


PEGS Summit

The PEGS Summit 2019 Survey is designed to help identify the major trends and challenges shaping the discovery, design, and development of biotherapeutics. The resulting report will provide a unique snapshot of where the industry is today, and where it is going over the next three years.

2019 Survey

PEGSummit.com






PEGS Summit 2019 Survey

The biologics industry is vibrant with promise and activity and Cambridge Healthtech Institute is at the nexus with events that have become the recognized standard in the community. In an effort to get a pulse on what the prospects and challenges are, CHI in conjunction with our publishing division, Cambridge Innovation Publishing, we have conducted one of the biggest surveys of its kind to identify the major trends and advancements shaping the discovery, design and development of biotherapeutics. The report provides a unique snapshot of where the industry is today, and where it is going over the next three years.


Which best describes your organization?



Answers for "Other"

Aptamer, Assay development, Bio control of plant disease, Biomarkers, Cell genetics, Clinical Fill Finish for area list above, Clinical Trials, Confidential, Cytokines, Drug therapies, "fviii, rare diseases", Glycoproteins, "Growth promoter, antibiotic, interferon", Health Care, HIV, Immunology, in vitro and in vivo models, "Innate immunity, inflammasome biology", Intrabodies, IVD, KINASE INHIBITORS, Lung Transplant, Messenger RNA-based vaccines, Microbes, Microencapsulation of active principles, Oligonucleotides and sugar, Organs-on-chip, PDX, Peptides, Pharmacogenetics, Prioritising drug targets, Protein Characterisation, Regulatory IM, Small molecule TGF-beta enhancers and antagonists, Specimen collection, Spectral Microscopy Histopathology, Stem cells and diabetes research, Supplements, Therapeutic peptides


In which area are you currently working in?







PEGS Summit 2019 Survey


Which phase of development is your project(s) currently in?




How positive are you about the biotherapeutics industry outlook in 2019?




What is the biggest challenge facing your drug development program?




Which emerging technology do you think will transform the biotherapeutics industry over the next 5 years?



What are the biggest challenges facing cancer immunotherapy?




Which targets offer the most promise in oncology?




Answers for "Other"

Cancer cell surface receptor, CD120, CD19, CD33, CD19, Checkpoint molecules, Discovery Immunotherapeutic, Plant origin, Natural Peptides, GCPR and eCS, G1TR; Dual targets, KRAS, Lysosomal proteins, Metabolic targets, Other ILs, PD-1, PD-L1, PD1, Pd1 and CTLA4, PD1/PD-L1, Personalised tumour antigen targets, TGF-beta, TRAIL


Aside from oncology, in which emerging indications are you most interested?




Where is your organization looking to invest in 2019?



In which service areas does your company plan to invest in over the next three years?




In which equipment does your company plan to invest in over the next three years?



What is the number one challenge facing antibody discovery and engineering?



How important do you think artificial intelligence and machine learning will be to your organization's future?





15th Annual
PEGS BOSTON
APRIL 8-12, 2019 | SEAPORT WORLD TRADE CENTER | BOSTON, MA

Healthtech Publishing

250 First Avenue, Suite 300, Needham, Massachusetts 02494

T: 781-972-5400 or toll-free in the U.S. 888-999-6288

F: 781-972-5425 • www.HealthtechPublishing.com